



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q68142

Tatsuki SHIOTA, et al.

Appln. No.: 10/031,698

Group Art Unit: 1617

Confirmation No.: 8252

Examiner: WANG, Shengjun

Filed: January 23, 2002

For: CYCLIC AMINE CCR3 ANTAGONIST

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/031,698

Q68142

from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: February 23, 2005



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Docket No: Q68142

Tatsuki SHIOTA, et al.

Appln. No.: 10/031,698

Group Art Unit: 1617

Confirmation No.: 8252

Examiner: WANG, Shengjun

Filed: January 23, 2002

For: CYCLIC AMINE CCR3 ANTAGONIST

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/031,698


Q68142

from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: February 23, 2005

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

FEB 23 2005
PATENT & TRADEMARK OFFICE

1 of 3

Complete if Known	
Application Number	10/031,698
Confirmation Number	8252
Filing Date	January 23, 2002
First Named Inventor	Tatsuki SHIOTA
Art Unit	1617
Examiner Name	WANG, Shengjun
Attorney Docket Number	Q68142

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,410,566		6/2002	Shiota et al.
		US 6,362,177		3/2002	Shiota et al.
		US 4,443,461		4/17/1984	Ward
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	00/69815	A	11/23/2000	M. Furuya, et al.	
		CN	1279668	A	01/10/2001	N. ENDO, et al.	Abstract
		WO	97/24325		7/1997		Abstract
		WO	98/04554		2/1998		Abstract

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		KRISHNA VADDI, "CHEMOKINE FACTS BOOK, ACAD. PRESS," 1997 San Diego, CA, pp. 1-2, 10-37, 86-130, 135-137, 142-143, 158-164.	
		FRANKLIN H. EPSTEIN, M.D, Luster, D. Andrew, "Chemokines - Chemotactic Cytokines that Mediate Inflammation", The New England Journal of Medicine (February 12, 1998), Vol. 338 pp. 436-445	
		MARCO BAGGIOLINI "Chemokines and leukocyte traffic" NATURE Vol. 392 pp. 565-568 April 9, 1998	
		JOSEPH HESSELGESER "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor" The Journal of Biological Chemistry Vol. 273, No. 25, June 19, 1998 pp. 15687-15692	
		European Communication 11/29/2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/031,698
				Confirmation Number	8252
				Filing Date	January 23, 2002
				First Named Inventor	Tatsuki SHIOTA
				Art Unit	1617
				Examiner Name	WANG, Shengjun
				Attorney Docket Number	Q68142



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	US				
	US				
	US				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³	Number ⁴		
	WO	97/44329		11/1997	
	WO	98/06703		2/1998	
	WO	98/30218		7/16/1998	Smithkline Beecham Corporation
	WO	98/25604		6/1998	
	WO	98/25605		6/1998	
	WO	98/25617		6/1998	
	WO	98/27815		7/1998	
	WO	98/31364		7/1998	
	WO	98/38167		9/1998	
	WO	98/02151		1/1998	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation ⁶
		BRIGHT, COLIN, et al. "Identification of a Non- Peptidic Rantes Antagonist, Vol. 1, No. 1, Bioorganic & Medicinal Chemistry Letters, 1998 pp. 771-774			
		WARD, G. STEPHEN, et al.. "Chemokines: understanding their role in T-lymphocyte biology", Biochem. J. (1998) 333, pages 457-470			
		European Communication 9/17/2003			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



PATENT & TRADEMARK OFFICE

Sheet 3 of 3

Complete if Known	
Application Number	10/031,698
Confirmation Number	8252
Filing Date	January 23, 2002
First Named Inventor	Tatsuki SHIOTA
Art Unit	1617
Examiner Name	WANG, Shengjun
Attorney Docket Number	Q68142

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		EP	903349				
		WO	00/9377				
		WO	00/31033				
		WO	00/35449				
		WO	00/35451				
		EP	1 201 239	A1	5/2/2002	Teijin Limited	
		WO	99/01127		1/14/1999	Smithkline Beecham Corporation	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		European Communication 9/17/2003	
		RAPPORT, CAROL A., et al., "Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for Rantes, MIP-1 β , and MIP-1 α ," The Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc., 1996, pages 17161-17166, Vol. 271, No. 29, Issue of July 19 th , USA.	
		MURAI, MASAKO, et al., "Active participation of CCR5 $^{+}$ CD8 $^{+}$ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease," The Journal of Clinical Investigations, July 1999, pages 49-57, Vol. 104, No. 1.	
		BALASHOV, KONSTANTIN E., "CCR5 $^{+}$ and CXCR3 $^{+}$ T cells are Increased in multiple sclerosis and their ligands MIP-1 α and IP-10 are expressed in demyelinating brain lesions," Proc. Natl. Acad. Sci., June 1999, pages 6873-6878, Vol. 90, USA.	
		BRADLEY, LINDA, et al., The Journal of Immunology, vol. 162(5), pp. 2511-2520, March 4, 1999	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to indicate here if English language Translation is attached.